Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are evaluating the safety, how the body processes, and how well the study medicine nirmatrelvirritonavir works for treating COVID-19 in children under 18 years old who are not hospitalized but at risk of severe illness. This trial is a Phase 3, open-label study focusing on nonhospitalized pediatric patients with COVID-19 to better understand the effects of this oral medication. The study medicine is given by mouth as tablets or powder twice daily for 5 days, totaling 10 doses. Different dosing forms and amounts are used depending on the participants age and weight, ranging from under 1 month old up to 18 years. Participants are assigned to one of several groups based on these factors to receive the medicine accordingly. During the study, participants will have blood samples taken to measure drug levels at specific times, and researchers will monitor for any side effects or changes in vital signs up to 34 days after starting treatment. They will also measure viral load through nasal swabs at several points over 28 days and assess hospitalizations or deaths related to COVID-19. Participants feedback on the medicines taste and acceptability will be collected during treatment.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying TIVDAK as a treatment option for patients with cervical cancer that has returned or spread after chemotherapy. The study aims to understand possible side effects of TIVDAK, especially those affecting the eyes. This is a phase 4 trial focusing on monitoring ocular safety in patients receiving this therapy. Participants will receive TIVDAK through an infusion into a vein every three weeks. Treatment continues until TIVDAK no longer works against the cancer. Eye exams are scheduled before treatment starts, before each of the first nine infusions, and then monthly for three months after stopping the drug to monitor any eye-related side effects. During the study, participants will have regular visits for eye assessments and clinical evaluations. Researchers will track the type, frequency, and severity of eye side effects up to 90 days after the last dose. They will also monitor serious adverse events, dose changes due to side effects, and the timing of eye issues. The study is expected to be completed by December 2028.
1-10 of 18
1